National Institutes of Health

Description

The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to continue follow-up of the Diabetes Prevention Program Outcomes Study (DPPOS) cohort through a collaborative cooperative agreement. The Diabetes Prevention Program (DPP) was a multi-center controlled clinical trial examining the efficacy of treatments to prevent or delay the development of type 2 diabetes in a population at high risk. The DPP demonstrated that either lifestyle change or the drug metformin could reduce the development of type 2 diabetes by 58% and 31%, respectively, compared with placebo. Following the end of DPP, the DPP cohort was enrolled in the DPPOS to determine the long-term effects of the DPP interventions on further diabetes development and microvascular complications. The primary purpose of this FOA is to support the DPPOS clinical centers to continue follow-up of the DPPOS cohort to examine the effectiveness of early metformin treatment on the development of cardiovascular disease and cancer. RFA-DK-15-505 will support continuation of the DPPOS Biostatistics Research Center.

Who can apply

• Public and State controlled institutions of higher education
• Private institutions of higher education

Contact

NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
FBOWebmaster@OD.NIH.GOV